The Price of Survival: Is Keytruda Worth What Merck Charges?
A Vial More Expensive Than Gold
In Guatemala, oncologist Julio Ramírez faced an impossible arithmetic. Dozens of his cancer patients could benefit from Keytruda, Merck’s blockbuster immunotherapy drug. He had authorization to treat exactly two. “What’s left for me to do? To play God,” Ramírez told investigators from the International Consortium of Investigative Journalists. The first patient through the door received the infusion. The rest received nothing.
That single 200-milligram dose cost roughly $11,000 in Guatemala—in a region where the average household earns about $700 a month. In the United States, the same dose carries a list price of approximately $12,000, and annual treatment can exceed $200,000. Meanwhile, a 100-milligram vial costs around $850 in Indonesia. The drug is chemically identical everywhere. The price is not.
Keytruda—generic name pembrolizumab—is the bestselling pharmaceutical product on Earth. In 2025, it generated $31.7 billion in revenue for Merck, nearly half the company’s total income and more than the entire National Football League earns in a season. Since its launch in 2014, cumulative sales have reached approximately $163 billion. The question is no longer whether Keytruda works. It does, sometimes miraculously. The question is whether its price reflects its value to patients—or its value to shareholders.
The Arithmetic of Survival
Merck’s senior vice president Johanna Herrmann has defended the company’s pricing by stating that Keytruda’s cost “reflects its value to patients and health-care systems.” CEO Robert Davis (1966– ) told a 2021 healthcare conference that the company needed to “focus efforts on reducing out-of-pocket cost.” Yet at a White House ceremony in December 2025 where pharmaceutical executives pledged to lower drug prices, Davis announced discounts on a diabetes drug and a cardiovascular pill. He said nothing about Keytruda.
The “value” argument rests on a familiar pillar: research and development costs. Davis testified to Congress that Merck invested $46 billion to research, develop, and manufacture Keytruda from 2011 to 2023. But those figures are, as Public Eye pharma specialist Patrick Durisch put it, “absolutely unverifiable.” An independent analysis by Public Eye, a Swiss nonprofit, estimated Keytruda’s actual R&D costs at $1.9 billion—roughly 1% of its global revenue. Even factoring in failed clinical trials, the estimate rises to $4.8 billion, or 3% of cumulative sales. The remaining 97% flows elsewhere: $75 billion in shareholder dividends, $43 billion in share buybacks, and a tax structure that routes profits through lower-tax jurisdictions.
These numbers dismantle the narrative that high prices are a necessary sacrifice at the altar of innovation. They reveal something more banal: a pricing mechanism designed not to recover costs but to extract maximum rents from desperation.
The Patent Fortress and the Art of Delay
Keytruda’s original patents expire in 2028. In any functioning market, this would herald the arrival of cheaper biosimilar competitors. But Merck has constructed what the Initiative for Medicines, Access and Knowledge (I-MAK) calls a “multi-pronged patent abuse scheme.” The ICIJ’s Cancer Calculus investigation, published in April 2026, mapped 1,212 patent applications across 53 countries—194 in the United States alone, 123 in Japan, 74 each in South Korea and Canada. Of these, 211 granted patents extend Keytruda’s market dominance through at least 2042, a full fourteen years past the original expiration. Another 337 pending applications could push that date even further. Eighty-four percent of all these filings came after Keytruda’s 2014 approval.
The strategy is known in the industry as “evergreening”—filing follow-on patents for minor modifications to dosage, formulation, or combination therapies that reset the exclusivity clock. Merck has also pursued a “product hop,” launching a subcutaneous injection version of Keytruda to shift patients to a newer formulation before generic competitors gain entry. Each patent application, as I-MAK founder Tahir Amin explained, becomes “a potential landmine” for would-be competitors. The cost of litigating through this thicket deters entry, delays access, and preserves pricing power.
The case of Argentina offers a revealing counterfactual. There, Merck held no enforceable patent. When a local firm, Elea, launched a cheaper biosimilar called PembroX in January 2025, Merck slashed its Keytruda price by 50% the day before. Competition accomplished overnight what years of advocacy had failed to achieve. Thousands more patients gained access. The Argentine experience raises an uncomfortable inference about every other market where Merck’s patent wall remains intact.
The Dosing Question No One Wants to Answer
There is another layer to this architecture of extraction. Merck recommends a fixed dose of 200 milligrams every three weeks for virtually all patients, regardless of body weight. Israeli oncologist Daniel Goldstein (1963– ), director of the Center for Cancer Economics at Rabin Medical Center, demonstrated in a 2017 study that this fixed-dosing protocol costs the U.S. healthcare system an additional $825 million annually compared to weight-based dosing. The World Health Organization has estimated that switching lung cancer patients alone to weight-based dosing could save $5 billion globally over fifteen years.
Clinical trials in India, Singapore, Malaysia, and Taiwan have shown that lower doses produce comparable results for certain cancer types. The Netherlands, Canada, and Israel have begun transitioning to weight-based protocols. Canadian oncologist Bishal Gyawali stated the matter plainly: “There is no scientific, medical, biological reason” for fixed dosing. “It’s just commercially motivated.”
When every unnecessary milligram is multiplied across millions of patients worldwide, the cumulative overspend becomes staggering—and the beneficiary is never the patient.
Who Lives, Who Dies, Who Decides
The human cost of this pricing architecture is distributed with brutal precision along lines of wealth and geography. In Mumbai, oncologist Amol Akhade surveyed the hundred patients waiting outside his clinic at Nair Hospital and estimated that seventy could benefit significantly from Keytruda. He could discuss the option with almost none of them. “They are hand-to-mouth daily wage workers,” he told ICIJ. “They are worried about where their next meal will come from.” A single month of Keytruda in India can equal more than twelve months of wages.
In South Korea, the situation is less catastrophic but no less instructive. The national health insurance system now covers Keytruda for thirteen cancer types across eighteen treatment protocols, with patients paying 5% of the cost under the serious illness special exemption—roughly 3.65 million won ($2,700) per year. The remaining burden falls on the public purse: hospitals billed the National Health Insurance Service over 400 billion won ($300 million) for Keytruda in 2025 alone, representing approximately 10% of all cancer drug expenditures. Following a major coverage expansion in January 2026, the government projects an additional 238.4 billion won in annual claims—yet the per-vial price dropped by a mere 3,000 won, less than three dollars.
In Brazil, thousands of patients sue their own government to access Keytruda. In the United Kingdom, the National Health Service has been paying up to five times the cost-effective price for certain lung cancer treatments with the drug. Across 51 countries, ICIJ identified 632 patients who turned to GoFundMe and similar platforms to crowdfund their Keytruda treatments. The Turkish Medical Association’s Nasır Nesanır posed the question that hangs over every one of these stories: “Should medical innovation be regarded as a common gain of humanity? Or should it remain a commercial asset under patent protection that deepens global inequality?”
Beyond Outrage: What a Just Price Might Look Like
The path forward requires dismantling the myth that current prices are inevitable. Argentina has demonstrated that competition works. India and Israel are proving that lower doses work. The Inflation Reduction Act in the United States will subject Keytruda to government price negotiation beginning in 2026, with new prices taking effect in 2028—a timeline Merck is racing to outflank through its subcutaneous formulation and patent extensions.
But regulatory patches alone will not suffice. The deeper structural issue is a global pharmaceutical system that permits companies to privatize publicly funded research—Keytruda’s foundational science emerged from decades of taxpayer-supported immunology work—while socializing the cost of failure and offloading unaffordable prices onto patients and public health systems. A just pharmaceutical order would require genuine transparency in R&D costs, mandatory licensing for essential medicines in countries that cannot afford market prices, international cooperation to prevent the kind of patent stacking that Merck has perfected, and weight-based dosing protocols grounded in clinical evidence rather than commercial interest.
A drug that can extend life should not be one that only the wealthy can afford to receive. Every vial of Keytruda that reaches a patient is a small victory against cancer. Every vial withheld by price is a quiet defeat for civilization. The cost of inaction is not measured in billions of dollars—it is measured in the silence of waiting rooms where doctors have learned not to mention the drug that might save their patients, because naming it would only add cruelty to suffering.
Post a Comment